399 related articles for article (PubMed ID: 21881388)
1. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
[TBL] [Abstract][Full Text] [Related]
2. Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Johnston SS; Bell K; Gdovin J; Jing Y; Graham J
Hosp Pract (1995); 2012 Feb; 40(1):15-23. PubMed ID: 22406879
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of prasugrel in a US managed care population.
Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
Olson WH; Ma YW; Crivera C; Schein J; Lefebvre P; Laliberté F; Dea K; Germain G; Lynch SM
J Med Econ; 2015; 18(12):1074-84. PubMed ID: 26407193
[TBL] [Abstract][Full Text] [Related]
6. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Norgard NB; Dinicolantonio JJ
Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
Olson WH; Ma YW; Laliberté F; Lefebvre P; Crivera C; Schein JR; Fields LE; Dea K; Germain G; Lynch SM
J Clin Pharm Ther; 2014 Dec; 39(6):663-72. PubMed ID: 25252190
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet options for secondary prevention in acute coronary syndromes.
Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Tcheng JE; Mackay SM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor for acute coronary syndrome?
Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
[TBL] [Abstract][Full Text] [Related]
14. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
[TBL] [Abstract][Full Text] [Related]
15. Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Vyas A; Bash LD; Patel MD; Simpson RJ
J Manag Care Spec Pharm; 2017 Sep; 23(9):947-956. PubMed ID: 28854078
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
J Manag Care Spec Pharm; 2018 Aug; 24(8):800-812. PubMed ID: 30058986
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
18. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
19. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
